Our platforms are based on our proprietary digital "Simoa" detection technology. We have recently had two EUAs approved for our COVID assays. A specific "detection" antibody is applied over the surface to bind to the antigen. However, one of the main issues with multiplexing can be the loss of sensitivity. By 2025, annual sales of the drug are estimated to reach $6.8 billion. SR-XWe commercially launched the SR-X instrument in the fourth quarter of 2017. Processing time for imaging a 96 well plate is less than five minutes. This patent family includes one granted U.S. patent. We may terminate the agreement at any time upon at least 60 days' written notice. Uman's Nf-L ELISA assay kit is classified as class B product. Risk Factor Summary Our business is subject to numerous risks and uncertainties. We cannot be certain that we will achieve or sustain profitability. &# A lack of future taxable income would adversely affect our ability to utilize these NOLs. Our NOLs may also be impaired under similar provisions of state law. Historically, most of our revenue has been denominated in U.S. dollars. Accordingly, we need highly trained technical support personnel. We face significant competition in the life sciences research and diagnostic markets. Also, the anticipated benefit of any acquisition may not materialize. We have focused initially on the life sciences research market. Reimbursement may impact the demand for those tests. Our Simoa bead-based technology is licensed to us by Tufts University. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. We use software licensed from third parties in our products. Item 1B. UNRESOLVED STAFF COMMENTSNot applicable.
